$Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study$

Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study

Background It is becoming increasingly important in the treatment of MM to improve our understanding of routine clinical practice and of the effectiveness of new agents and regimens outside the clinical trial setting. UVEA-IXA is a European, multicenter, observational, longitudinal cohort study of R...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.42-44
Hauptverfasser:	Ludwig, Heinz, Terpos, Evangelos, Mateos, María-Victoria, Boccadoro, Mario, Kishore, Bhuvan, Ramasamy, Karthik, Fernandez, Sylvie, Ferri, Fabio, Bent-Ennakhil, Nawal, Zomas, Athanasios, Gavini, François, Hajek, Roman
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!